Tailoring treatment to risk in type 2 diabetes

British Journal of General Practice

Volumn 60, Issue 572, 2010, Pages 158-160

  Graffy, Jonathan ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA BASE; DISEASE ASSOCIATION; DRUG COST; DRUG SAFETY; EDITORIAL; FOLLOW UP; GENERAL PRACTICE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INDEPENDENT VARIABLE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; UNITED KINGDOM; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS;

EID: 77951526301     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: 10.3399/bjgp10X483463     Document Type: Editorial

References (14)

1. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes (update) - CG66. London: NICE, 2008.
2. Lehman R, Krumholz HM. Tight control of blood glucose in long standing type 2 diabetes. BMJ 2009; 338: b8OO. DOI: 10.1136/bmj.b800.
3. National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes - CG87. London, NICE, 2009.
4. Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 2007; 30(9): 2399-2400.
5. Landman GW, van Hateren KJJ, Kleefstra N, et al. The relationship between glycemic control and mortality in patients with type 2 diabetes in general practice (ZODIAC-U). Br J Gen Pract 2010; 172-175.
6. Elley CR, Kenealy T, Robinson E, Drury PL Glycated haemoglobin and cardiovascular outcomes in people with Type 2 diabetes: a large prospective cohort study. Diabet Med 2008; 25(11): 1295-1301.
7. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001; 322(7277): 15-18.
8. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N Engl J Med 2008; 358(24): 2545-2559.
9. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24): 2560-2572.
10. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360(2): 129-139.
11. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577-1589.
12. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. The Lancet 2010; 375(9713): 481-489.
13. American Diabetes Association. Standards of Medical Care in Diabetes - 2010. Diabetes Care 2010; 33(Suppl l):S11-S61.
14. National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents for blood glucose control: costing report London: NICE, 2009. http://guidance.nice.org.uk/CG87/CostReport/pdf/Eng DOI: 10.3399/bjgpl0X483463